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Modest Reductions in Dose Intensity and Drug-Induced
Neutropenia have No Major Impact on Survival of Patients
with Non-small Cell Lung Cancer Treated with Platinum-
Doublet Chemotherapy
Andre T. Brunetto, MD, Craig P. Carden, FRACP, James Myerson, MD, Ana Luisa Faria, MD,
Sue Ashley, PhD, Sanjay Popat, MRCP, PhD, and Mary E. R. O’Brien, MD, FRPC
Background: Previous studies investigating the effect of increased
dose intensity and chemotherapy-induced neutropenia in patients
with advanced non-small cell lung cancer (NSCLC) have not con-
sistently shown significant survival benefits.
Methods: This retrospective analysis reviewed the outcome of
patients receiving palliative chemotherapy for advanced NSCLC
(stages III–IV) at the Royal Marsden Hospital. Regimens included
cisplatin or carboplatin with either vinorelbine or gemcitabine on
days 1 and 8, every 21 days. Patients who received at least four
cycles of chemotherapy were classified into groups based on dose
intensity, dose reductions, and worst grade of neutropenia for a
landmark analysis. Comparisons between these groups for time to
progression and overall survival were made by standard univariate
and multivariate methods.
Results: One hundred sixty-nine of a total of 190 patients who
received more than four cycles of chemotherapy during the period
between November 1998 and December 2008 were included. One
hundred twenty-five (73.9%) patients received four chemotherapy
cycles with the remaining receiving up to six cycles. The median
relative dose intensity for platinum was 93.9% (62.1–102%) and for
vinorelbine/gemcitabine was 91.7% (37.8–105%). Dose reductions
were recorded in 64 patients (37.8%), and 65 patients (38.5%) had
grades 3 to 4 neutropenia. There were no statistically significant
differences in time to progression and overall survival between any
of the subgroups.
Conclusions: This retrospective analysis demonstrates no signifi-
cant relationship between survival and dose intensity (90%),
modest dose reductions (20%), or chemotherapy-induced neutro-
penia in patients receiving standard doublet platinum containing
chemotherapy in NSCLC.
Key Words: NSCLC, Dose intensity, Neutropenia, Dose reduction,
Progression-free survival, Overall survival.
(J Thorac Oncol. 2010;5: 1397–1403)
Lung cancer is one of the leading causes of cancer-relateddeath worldwide, and 70% of patients present with
locally advanced or metastatic disease at the time of diagno-
sis.1 Non-small cell lung cancer (NSCLC) accounts for 85%
of all lung cancer cases in the United States, and, in advanced
disease, chemotherapy has a modest but significant impact on
survival and quality of life. A two-drug platinum-based
regimen is standard for patients with good performance status
(PS), resulting in a median overall survival (OS) of approx-
imately 8 months and a 10% absolute improvement in the
1-year survival rate.2,3 In the elderly, when compared with
best supportive care, single-agent chemotherapy also signif-
icantly improves survival and quality of life and can be an
alternative in patients with poor PS.4
Dose-intense chemotherapy regimens supported by
growth factors have improved survival for some solid cancer
types, such as the adjuvant management of breast cancer, and
are accepted standard of care.5,6 Dose-dense regimens sup-
ported by growth factors in small-cell lung cancer (SCLC)
and dose-intense regimens in NSCLC have not yet shown any
survival benefit and are not recommended.7–9 Interestingly, a
few studies using chemotherapy for breast cancer, osteosar-
coma, ovarian cancer, and SCLC have shown that the induc-
tion of neutropenia is associated with statistically superior
outcomes.10–15
Banerji et al.15 showed in our retrospective series of
SCLC that patients who developed grades 0 to 2 neutropenia
had a median survival of 47 weeks compared with 60 weeks
in those patients achieving grades 3 to 4 neutropenia (p 
0.008). Notably, this was only statistically significant in the
limited stage subgroup. In addition, Di Maio et al.16 published
a retrospective meta-analysis of three randomized studies,
using either single agent or platinum-doublet chemotherapy
for advanced NSCLC and showed that the presence of drug-
induced neutropenia of any grade predicted for a superior
outcome. A recent Japanese study looking at patients with
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NSCLC in a randomized phase III trial also showed that
chemotherapy-induced neutropenia was an independent prog-
nostic factor for an improved outcome.17
In the setting of palliative chemotherapy for NSCLC,
tumors are often chemoresistant, and the patient population is
relatively elderly, with associated comorbidities, poor PS,
and an increased risk of life-threatening complications.18,19 It
remains unclear whether modest dose reductions or dose
delays in this population are associated with adverse outcome
and whether drug-induced neutropenia is necessary for im-
proved survival. Therefore, we performed a retrospective
audit in an unselected population with advanced NSCLC
treated with platinum doublet chemotherapy to provide prac-
tical information on whether dose intensity and hematological
toxicity of treatment correlate with outcome.
METHODS
Population
All patients with locally advanced or metastatic
NSCLC who had received at least four cycles of first-line
platinum-containing doublet chemotherapy at standard dose
outside the context of a clinical trial between November 1998
and December 2008 were eligible. After excluding 21 pa-
tients from the analysis who had received radical radiother-
apy, adjuvant chemotherapy, targeted agents, nonstandard
doses of chemotherapy or rechallenged with second-line
doublet chemotherapy, 169 patients were included in this
analysis. Baseline characteristics including the date of initial
diagnosis, histology, staging, chemotherapy regimen, and
radiologic assessment for each patient were retrieved from
the hospital electronic patient database. In addition, the doses,
dates of administration, and total neutrophil counts on days 1
and 8 were recorded for every cycle of chemotherapy. Pa-
tients who had fewer than four cycles of chemotherapy were
not included in the analysis, because they may have had an
inconsistent effect on treatment outcomes (time to progres-
sion [TTP] and OS) because of relative chemoresistance.
Chemotherapy Regimens
Chemotherapy consisted of one of the following intra-
venous (IV) combinations repeated every 21 days: (a) carbo-
platin area under the curve 5 day 1, gemcitabine 1.25 g/m2
day 1, and day 8 IV; (b) carboplatin area under the curve 5
day 1, vinorelbine 25 mg/m2 day 1, and day 8 IV; (c) cisplatin
75 mg/m2 day 1, gemcitabine 1.25 g/m2 day 1, and day 8 IV;
and (d) cisplatin 75 mg/m2 day 1, vinorelbine 30 mg/m2 day
1 and day 8 IV. A total of 14 patients received oral vinorel-
bine 60 mg/m2 on day 8 in substitution to the IV preparation.
There was no routine prophylactic use of antibiotics and/or
growth factors.. If the patients were admitted with febrile
neutropenia, G-CSF was administered until the neutrophil
count was 1.0  109/liter.
Rates of Neutropenia
Full blood counts were checked routinely on days 1 and
8 before chemotherapy dosing and at any outpatient assess-
ment or inpatient admission. The worst grade of neutropenia
recorded during cycles 1 to 4 was used for analysis and was
graded per National Cancer Institute Common toxicity crite-
ria (CTC) version 3; grades: 0  2.0  109/liter, I  2.0 to
1.5  109/liter, II  1.5 to 1.0  109/liter, III  1.0 to 0.5 
109/liter, and IV0.5 109/liter. Chemotherapy was only
administered when an absolute neutrophil count of 1.5 
109 was achieved. We did not plan to analyze beyond four
cycles of chemotherapy because the numbers were thought to
be small and patients going beyond this are highly selected
and generally fitter. In addition, the risk of neutropenia may
increase with the number of chemotherapy administrations
and could potentially bias results.
Calculation of Relative Dose Intensity
Dose intensity is defined as the amount of drug (usually
in mg/m2) delivered to a patient in a week of treatment.20
Achieved dose intensity was determined as the total dose of
individual drug received in the first four cycles for each
individual agent per body surface area divided by the number
of days from the beginning (cycle 1 day 1) to end (cycle 4 day
21) of treatment for every patient. Relative dose intensity
(RDI) for each individual drug was calculated and defined as
the achieved dose intensity relative to the standard (target)
schedule with a 3-week interval between treatments. Dose
reduction was considered for any individual drug at any time
point in the first four cycles and should be inferior to 20% of
initial starting dose. Average dose-intensity values for each
individual drug and 95% confidence intervals (CIs) will not
be detailed in this article. Statistical distributions for RDI and
treatment duration will be provided.
Statistical Methods
The primary endpoints of the study were TTP and OS.
Computed tomography scans were performed after cycles 2,
4, and 6 and were evaluated by RECIST or WHO before the
year of 2002. Patients with continued partial response after
four chemotherapy cycles and good tolerance to treatment
were offered two additional cycles. Dose intensity, dose
reductions, and grades of neutropenia beyond cycle 4 were
not analyzed. TP and OS were calculated according to dose
intensity of regimen 90% versus 90%; worst grade of
neutropenia: 0 to 2 versus 3 to 4 and 0 versus 1 to 4; and
presence versus absence of dose reduction.
A 90% cutoff for RDI was used as this represented the
approximate median and was considered to be a clinically
meaningful reduction rather than unintended drug delays. OS
and TTP were calculated by the Kaplan-Meier method, and
differences between groups were assessed by the log-rank test
and Fisher’s exact test. Patients were eligible for inclusion in
the analysis only after they had received four courses of
chemotherapy; for this reason, the survival analysis used a
landmark approach and both OS and TTP were measured
from the date of starting the fourth course of treatment until
death from any cause (OS) and progression in any site (TTP).
Patients were censored for survival at last follow-up visit.
TTP was the date that computed tomography documented
progressive disease, or there was symptom progression. Rou-
tine scans after the end of treatment were not planned, and
therefore, the TTP is probably longer than in reported clinical
trials. A multivariate analysis, using Cox’s proportional haz-
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ards model was also performed to adjust for the effects of
age, gender, stage of disease, and PS. The study proposal was
reviewed and approved by the institutional audit committee.
RESULTS
Patient Demographics
One hundred sixty-nine patients were studied, and de-
mographics are shown in Table 1. The male/female ratio was
1.22:1, and the median age was 63 years (range, 33–86).
Thirty-seven (21.8%) patients received carboplatin/gemcitab-
ine, 73 (43.1%) patients received carboplatin/vinorelbine, 13
(7.7%) patients received cisplatin/gemcitabine, and 46
(27.2%) patients received cisplatin/vinorelbine. Sixty
(35.5%) patients had stage IV disease at diagnosis. One
hundred twenty-five patients (73.9%) received four cycles of
chemotherapy and only 27 patients (16%) completed six
cycles. Twenty of 189 (10.5%) of patients had an Eastern
Cooperative Oncology Group PS of 2.
In the multivariate analysis, none of the variables (age,
sex, stage, and PS) were significant predictors of OS. In the
multivariate analysis of TTP, disease stage was the only
significant prognostic factor (stage 3 versus stage 4, p 
0.01). There was no difference in OS (p  0.2) or TTP (p 
0.9) between patients on vinorelbine versus those on gemcit-
abine. The median response rate was 56.5% (range: 43.7–
61.7%), and there were no significant differences in the
response rates between cisplatin and carboplatin (p  0.4)
nor between vinorelbine and gemcitabine groups (p  0.7).
Relationship of RDI to Survival Outcomes
The median duration of treatment for all patients was 90
days (range: 82–121 days). The median platinum RDI was
93.9% (range: 62.1–102%) for all four chemotherapy groups in
combination. The median vinorelbine/gemcitabine RDI was
91.7% (range: 37.8–105%). The lower dose intensity in the
nonplatinum group was due to frequent omissions, and not
delays, of day 8 chemotherapy because of hematological and
nonhematological toxicity. There were no statistical treatment
differences between any of the groups for RDI or total duration
of treatment. Individual values are detailed in Table 2.
There was no OS difference in patients stratified by
platinum RDI using the landmark approach. The median OS
for patients with RDI of platinum 90% was 62 weeks (95%
CI: 34–90 weeks) versus 58 weeks (95% CI: 45–70 weeks) in
those with RDI 90%, p  0.4. Similarly, in patients
stratified by vinorelbine or gemcitabine RDI, there was no
significant survival difference. The median OS for patients
with RDI of vinorelbine 90% was 51 weeks (95% CI:
45–56 weeks) versus 58 weeks (95% CI: 45–72 weeks) in
those with RDI 90%, p  0.3. The median OS for patients
with RDI of gemcitabine 90% was 79 weeks (95% CI:
48–111 weeks) versus 76 weeks (95% CI: 49–103 weeks) for
those with RDI 90%, p  0.6 (Fig. 1). In addition, there
was no statistical meaningfully differences between the dose
intensities for the individual agents. TTP for platinum and
nonplatinum agents also showed no statistically significant
differences. All results are shown in Figure 1.
Relationships of Dose Reduction and Degree
of Neutropenia to Survival Outcomes
Sixty-four patients (37.8%) received dose reductions,
ranging from 22 to 51% across all chemotherapy treatment
TABLE 1. Demographics
Treatment
Carbo/
Gem
Carbo/
Vin
Cis/
Gem
Cis/
Vin Total
Patients Total 37 73 13 46 169
Gender Female 20 31 7 18 76
Male 17 42 6 28 93
Age Median 65 64 58 59 63
Range 33–86 39–78 50–70 35–73 33–86
Pathology Adeno 11 22 7 19 59
BAC 0 1 0 0 1
SCC 17 27 4 16 64
Large cell 0 2 0 1 3
Other 1 8 1 3 13
Not known 8 13 1 7 29
Stage IIIa 7 15 1 13 36
IIIb 14 32 9 17 72
IV 16 26 3 16 60
PS 0 1 5 1 4 11
1 25 43 12 35 115
2 7 10 0 3 20
Not known 4 15 0 4 23
Courses 4 27 54 10 34 125
5 1 10 1 5 17
6 9 9 2 7 27
Carbo, carboplatin; gem, gemcitabine; vin, vinorelbine; cis, cisplatin; PS, perfor-
mance status; courses, courses of chemotherapy; stage, stage of disease by tumor, node,
metastasis; adeno, adenocarcinoma; BAC, broncoalveolar carcinoma; SCC, squamous
cell carcinoma.
TABLE 2. Duration of Treatment and Relative Dose
Intensity (RDI)a,b
Mean (d) Median (d) Range
All patients 90.7 90 82–121
Carbo/gem 91.6 91 82–119
Carbo/vin 90.9 89 84–121
Cis/gem 88.2 84 84–98
Cis/vin 90.5 88 83–112
Platinum Mean (RDI) (%) Median (RDI) (%) Range (%)
All patients 92.5 93.9 62.1–102
Carbo/gem 91.3 93.8 65.0–102
Carbo/vin 92.6 94.6 62.1–101
Cis/gem 96.4 100 86.8–100
Cis/vin 92.0 93.8 69.6–101
Vin/Gem Mean (RDI) (%) Median (RDI) (%) Range (%)
All patients 88.9 91.7 37.8–105
Carbo/gem 85.3 87.6 37.8–102
Carbo/vin 89.2 92.6 41.8–105
Cis/gem 93.6 94.9 75.4–100
Cis/vin 89.8 93.5 57.8–101
a Duration of treatment  defined as date cycle 4 d 1  date cycle 1 d 1  21 d.
b Relative dose intensity  percentage (%) intended drug delivered per week.
Carbo, carboplatin; gem, gemcitabine; vin, vinorelbine; cis, cisplatin.
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groups. The carboplatin/gemcitabine combination had the
highest rate of dose reduction (51%), but there was no
statistically significant difference in rates between the four
doublets (p  0.5). Nine patients changed from cisplatin to
carboplatin as a consequence of hearing loss, tinnitus, peripheral
neuropathy, or loss of renal function. The reasons for dose
reductions were mostly due to hematological toxicity, neutro-
penic sepsis/fever, and decline in PS. There was no difference in
OS or TTP for those patients who had a dose reduction com-
pared with those who did not. The median OS for the no
reduction group was 65 weeks (95% CI: 47–83 weeks) versus
53 weeks (95% CI: 44–62 weeks) in the dose reduction group
FIGURE 1. Overall survival (OS) and time-to-progression (TTP) curves for platinum (carboplatin and cisplatin), vinorelbine
(navelbine), and gemcitabine using the landmark method (cycle 4 d 1, start point). None of the survival curves demonstrate
any significant association between relative dose intensity (RDI) and outcomes (OS and TTP) for any of the chemotherapy
agents.
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(p  0.1). The median TTP for the no reduction group was 29
weeks (95%CI: 19–38 weeks) versus 21 weeks (95%CI: 13–29
weeks) in the reduction group (p  0.4).
The worst recorded grade of neutropenia in the first
four cycles across all four groups were G0  22.5%; G1 
16.6%; G2: 22.5%; G3: 17.8%; and G4  20.7%. The
median worst grade of neutropenia (grade 3/4) was 39.95%
(range: 34.2–45.7%), and all values are shown on Table 3.
There was no difference in OS or TTP in patients who had
grades 3 to 4 neutropenia as opposed to those who had grades
0 to 2 neutropenia. The median OS for grades 0 to 2
neutropenia was 59 weeks (95% CI: 44–73 weeks) versus 54
weeks (95% CI: 45–63 weeks) for those with grades 3 to 4
neutropenia (p  0.9). The median TTP for grades 0 to 2
neutropenia was 26weeks (95% CI: 20–32 weeks) versus
26weeks (95% CI: 12–40 weeks) for grades 3 to 4 neutro-
penia (p 0.7). There were also no differences in OS or TTP
for patients who had no neutropenia compared with those
who had any grade (1–4) of neutropenia. The median OS for
those patients with grade 0 neutropenia was 53 weeks (95%
CI: 29–77weeks) versus 58 weeks (95% CI: 48–68 weeks)
for those with grades 1 to 4 neutropenia (p  0.9). The
median TTP for grade 0 neutropenia was 20 weeks (95% CI:
5–35 weeks) versus 26 weeks (95% CI: 20–33 weeks) for
grades 1 to 4 neutropenia (p  0.8). The OS survival graphs
for drug-induced neutropenia are shown in Figure 2.
DISCUSSION
The median survival of patients with advanced NSCLC
is less than 1 year. Palliative chemotherapy is known to
improve quality of life and OS.2–4 The survival rates in this
study are higher than usually reported because only patients
who completed four cycles of chemotherapy were included in
the analysis and are accordingly a better prognostic group.
The landmark method used in this study consists of a valid
approach to compare survival curves determined at a fixed
time point (here cycle 4 day 1) and was used to adjust for TTP
and OS avoiding potential bias in time delays before com-
pletion of cycle 3. The lower dose intensity/dose-reduction
groups and those patients with higher grades of neutropenia
were expected to have delays in the first 3 cycles of treatment
and potentially confound results. The landmark analysis can
also help to interpret maintenance trials with designs that
randomize for switch or continuation of treatment.
Pathology, age, gender, stage, and PS were not signif-
icantly dissimilar between chemotherapy regimens and com-
parable with other unselected groups undergoing palliative
chemotherapy for NSCLC in the literature.1–3
There was no significant benefit seen in TTP or OS in
the stratified groups for dose intensity or modest dose reduc-
tion. The average figures for dose intensity were around 80%
and above for all drugs, but there was a wide range. Although
retrospective and of relatively small numbers of patients, this
data support current practice in modest dose adaptation ac-
cording to toxicity.
The use of hematological toxicity to guide selection of
appropriate chemotherapy doses is based on the expectation
that the more myelotoxic dose is also likely to be more
cytotoxic and efficacious. Experience derived from a wide
range of tumor types has shown an association between
TABLE 3. Rates of Neutropenia Across All Four Chemotherapy Groups
Worst Grade
of Neutropenia
Carboplatin 
Gemcitabine (%)
Carboplatin 
Vinorelbine (%)
Cisplatin 
Gemcitabine (%)
Cisplatin 
Vinorelbine (%) Total (%)
Grade 0 7 (18.9) 21 (28.8) 4 (30.8) 6 (13) 38 (22.5)
Grade 1 5 (13.5) 12 (16.4) 1 (7.7) 10 (21.7) 28 (16.6)
Grade 2 11 (27.9) 15 (20.5) 3 (23.1) 9 (19.6) 38 (22.5)
Grade 3 9 (24.3) 10 (13.7) 3 (23.1) 8 (17.4) 30 (17.8)
Grade 4 5 (13.5) 15 (20.5) 2 (15.4) 13 (28.3) 35 (20.7)
Total 37 (100) 73 (100) 13 (100) 46 (100) 169 (100)
The worst grade of neutropenia for each chemotherapy doublet in the first four cycles of treatment is shown. No significant differences between groups are demonstrated.
FIGURE 2. OS curves are shown using the landmark
method for different grades of neutropenia. Worst grades of
neutropenia (02 vs. 34) and (0 vs. 14) are compared,
and no significant difference between groups is demon-
strated.
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chemotherapy-induced neutropenia and improved out-
comes.5,6,10–15 Our retrospective data suggest that this may
not be the case for palliative chemotherapy using platinum
doublet in NSCLC. Although we only monitored day 1 and
day 8 blood counts in asymptomatic patients, we did see rates
of grades 3 and 4 neutropenia of around 40%, which is as in
the reported studies using these regimens. The study of Di
Maio et al.16 showed that 21% of patients experienced grades
3 to 4 neutropenia, and this proportion was higher in the
cohort of patients receiving cisplatin-based doublet (23%
with cisplatin-gemcitabine and 35% with cisplatin-vinorel-
bine).16 Kishida et al.17 also showed chemotherapy-induced
neutropenia as a prognostic factor in NSCLC. In their study,
387 patients with good PS (Eastern Cooperative Oncology
Group: 0–1) who underwent palliative chemotherapy for
advanced disease in a randomized phase III trial received
either a standard platinum doublet (carboplatin and pacli-
taxel) or a nonplatinum containing regimen (vinorelbine and
gemcitabine followed by docetaxel). The adjusted hazard
ratio for patients who developed no neutropenia was 0.59
(95% CI, 0.36–0.97), and the incidence of grade 3/4 neutro-
penia was not significantly different to our population.
We did not miss any symptomatic neutropenia, and
therefore, although we did not take blood counts on days 10
to 15, our rates are a reasonable measure of chemotherapy-
induced neutropenia with specific regimens.
As the curves for both dose intensity and neutropenia
really show no difference, any future planned trials in this
area should be powered to show a difference that is small in
magnitude, and thus, large numbers of patients would be
necessary.
What are the likely reasons for this difference in pa-
tients with NSCLC compared with other tumor types? A
potential reason may be the comorbidities found in this
patient group given the usual significant history of smoking
and associated cardiovascular and respiratory complications.
These are likely to confound the effects of chemotherapy.
The study of Banerji et al.15 in our institution showed a
significant difference for TTP and OS in patients with SCLC
who had similar demographic parameters and characteristics
as to our population in general. However, this difference was
only observed on limited stage SCLC, and maintenance of
dose intensity may be more important in the curative setting,
as seen with adjuvant treatment of breast cancer.5,6
Genetic factors modulating chemoresistance to plati-
num agents and their association with clinical outcomes in
NSCLC have been recently reported in several studies.21–24
Increased expression of the DNA repair enzyme ERCC1 has
been associated with worse outcome in patients with NSCLC
treated with cisplatin-based chemotherapy21 and has also
been used to predict response to platinum-based treatment.25
Induction of neutropenia and dose intensity may be of less
value in this population where platinum agents are the main-
stay of treatment.
Our figures may be due to a small number of patients
with a phenotypic great sensitivity to the drugs, who derived
a large benefit from the treatment and, therefore, may only
have needed a small dose of the right combination. Indeed,
this group may have also been predisposed to toxicity and,
therefore, dose reduction. We are now seeing this in patients
with an epidermal growth factor mutation who are treated
with a tyrosine kinase inhibitor and remains to be defined for
the rest of the NSCLC population.
We appear to have reached a plateau in many ways with
standard therapies in NSCLC and, until more specific meth-
ods of selecting drugs for patients are available, we can only
accept that as far as we can assess, modest reductions in dose
intensity are not detrimental to time to treatment failure and
overall patient survival.
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